Nrf2 Activation by SK-119 Attenuates Oxidative Stress, UVB, and LPS-Induced Damage.


Journal

Skin pharmacology and physiology
ISSN: 1660-5535
Titre abrégé: Skin Pharmacol Physiol
Pays: Switzerland
ID NLM: 101188418

Informations de publication

Date de publication:
2019
Historique:
received: 02 10 2018
accepted: 05 03 2019
pubmed: 13 5 2019
medline: 10 1 2020
entrez: 13 5 2019
Statut: ppublish

Résumé

The Nrf2 signaling pathway plays a pivotal role in neutralizing excess reactive oxygen species formation and therefore enhancing the endogenous cellular protection mechanism. Thus, activating this pathway may provide therapeutic options against oxidative stress-related disorders. We have recently applied a computer-aided drug design approach to the design and synthesis of novel Nrf2 enhancers. The current study was aimed at investigating the potential beneficial impact of (E)-5-oxo-1-(4-((2,4,6-trihydroxybenzylidene)amino)phenyl)pyrrolidine-3-carboxylic acid (SK-119) in skin oxidative damage models. SK-119, tested initially in PC-12 cells, attenuated oxidative stress-induced cytotoxicity concomitantly with Nrf2 activation. The potential impact of this compound was evaluated in skin-based disease models both in vitro (HaCaT cells) and ex vivo (human skin organ culture). The data clearly showed the marked anti-inflammatory and photoprotection properties of the compound; SK-119-treated cells or tissues displayed a reduction in cytokine secretion induced by lipopolysaccharides (LPS) in a manner comparable with dexamethasone. In addition, topical application of SK-119 was able to block UVB-induced oxidative stress and attenuated caspase-mediated apoptosis, DNA adduct formation, and the concomitant cellular damage. These results indicate that SK-119 is an Nrf2 activator that can be used as a prototype molecule for the development of novel treatments of dermatological disorders related to oxidative stress.

Sections du résumé

BACKGROUND/AIMS OBJECTIVE
The Nrf2 signaling pathway plays a pivotal role in neutralizing excess reactive oxygen species formation and therefore enhancing the endogenous cellular protection mechanism. Thus, activating this pathway may provide therapeutic options against oxidative stress-related disorders. We have recently applied a computer-aided drug design approach to the design and synthesis of novel Nrf2 enhancers. The current study was aimed at investigating the potential beneficial impact of (E)-5-oxo-1-(4-((2,4,6-trihydroxybenzylidene)amino)phenyl)pyrrolidine-3-carboxylic acid (SK-119) in skin oxidative damage models.
METHODS METHODS
SK-119, tested initially in PC-12 cells, attenuated oxidative stress-induced cytotoxicity concomitantly with Nrf2 activation. The potential impact of this compound was evaluated in skin-based disease models both in vitro (HaCaT cells) and ex vivo (human skin organ culture).
RESULTS RESULTS
The data clearly showed the marked anti-inflammatory and photoprotection properties of the compound; SK-119-treated cells or tissues displayed a reduction in cytokine secretion induced by lipopolysaccharides (LPS) in a manner comparable with dexamethasone. In addition, topical application of SK-119 was able to block UVB-induced oxidative stress and attenuated caspase-mediated apoptosis, DNA adduct formation, and the concomitant cellular damage.
CONCLUSION CONCLUSIONS
These results indicate that SK-119 is an Nrf2 activator that can be used as a prototype molecule for the development of novel treatments of dermatological disorders related to oxidative stress.

Identifiants

pubmed: 31079103
pii: 000499432
doi: 10.1159/000499432
doi:

Substances chimiques

Benzylidene Compounds 0
Cytokines 0
Lipopolysaccharides 0
NF-E2-Related Factor 2 0
Pyrrolidines 0
Caspase 3 EC 3.4.22.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-181

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Shirin Kahremany (S)

Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat Gan, Israel.
Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

Ilana Babaev (I)

Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat Gan, Israel.

Raanan Gvirtz (R)

The Skin Research Institute, The Dead-Sea and Arava Science Center, Masada, Israel.

Navit Ogen-Stern (N)

The Skin Research Institute, The Dead-Sea and Arava Science Center, Masada, Israel.

Salome Azoulay-Ginsburg (S)

Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat Gan, Israel.

Hanoch Senderowitz (H)

Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat Gan, Israel.

Guy Cohen (G)

The Skin Research Institute, The Dead-Sea and Arava Science Center, Masada, Israel.

Arie Gruzman (A)

Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, Ramat Gan, Israel, gruzmaa@biu.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH